- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life
Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.
EP: 1.Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer
EP: 2.Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer
EP: 3.Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles
EP: 4.ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer
EP: 5.Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer
EP: 6.Elacestrant: Treatment Considerations, Including Dosing and Compliance
EP: 7.Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life
EP: 8.Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer
EP: 9.Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer
EP: 10.Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer
EP: 11.The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer
EP: 12.Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
EP: 13.Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones discusses toxicities associated with oral selective estrogen receptor degraders (SERDs) with Vidal, Callahan, and Gradishar. Vidal addresses cardiovascular, reproductive, and bone health, noting potential toxicities in some oral SERDs but emphasizing their overall well-tolerated nature and how they provide clinicians with effective alternatives to chemotherapy. Callahan delves into nausea and gastrointestinal toxicities, citing a learning curve and advising patients to take the drug with food to minimize adverse effects. The patient-reported outcomes data presented at the 2023 European Society for Medical Oncology Congress suggests an improvement in patient-reported nausea and vomiting, enhancing the overall experience. Gradishar emphasizes that oral SERDs, particularly elacestrant, maintain quality of life with minimal adverse effects and improved tolerability compared with chemotherapy. Vidal highlights the evolving landscape of prior authorization, acknowledging initial challenges but noting improved processes, voucher programs, and timely access to drugs, which streamlines the patient experience. This discussion offers a comprehensive view of the toxicities associated with oral SERDs and insights into managing patient experiences in clinical practice.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
